ImmunID leverages the power of the adaptive immune system to develop innovative diagnostic and therapeutic solutions, a field they refer to as Immune Medicine. Their platform utilizes advanced technologies such as adaptive immunosequencing, which allows for the detailed analysis of T-cell receptor (TCR) repertoires. This technology is pivotal in understanding immune responses and is applied in various areas, including minimal residual disease (MRD) detection, drug discovery, and the development of TCR and antibody therapeutics. By harnessing rich immune receptor data, ImmunID aims to inform clinical trials and facilitate the creation of transformative medicines.

The company's focus on MRD involves highly sensitive next-generation sequencing (NGS) techniques that enhance the assessment of residual disease in clinical practice and drug trials. This capability is crucial for improving patient outcomes by enabling earlier detection and more effective treatment strategies. Additionally, ImmunID's research and development efforts are centered around decoding public T-cell signatures of disease, which contributes to a deeper understanding of immunological responses and the complexities of various diseases. Through these advanced methodologies, ImmunID is positioned to make significant strides in the field of immune medicine, ultimately aiming to transform disease detection and treatment paradigms.

France

Adaptive Biotechnologies is a pioneer and leader in immune-driven medicine that aims to improve people's lives by learning from the wisdom of their adaptive immune systems. Adaptive's proprietary immune profiling platform reveals and translates insights from our adaptive immune systems with unprecedented scale and precision. Working with drug developers, clinicians and academic researchers, we are applying these insights to develop products that will transform the way diseases -- such as cancer, autoimmune conditions, and infectious diseases -- are diagnosed and treated. For more information, please visit adaptivebiotech.com.

ImmunID

Company Details